Navigation Links
Savient Submits Biologics License Application (BLA) for pegloticase
Date:10/31/2008

ts contain these identifying words. In particular, any statements regarding the pegloticase BLA filing, request for priority review, clinical results of the Phase 3 pivotal clinical trials and the ongoing Open Label Extension (OLE) program for pegloticase, the timing of approval of the BLA, and the market for pegloticase, are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our current assessment of the Phase 3 clinical data and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the delay or failure in completing development of pegloticase and developing other product candidates; our stock price and market conditions, varying interpretations of our clinical and CMC data by the FDA, delay achieving or failure to achieve FDA approval of pegloticase, difficulties of expanding our product portfolio through in-licensing or acquisition; inability to manufacture commercial quantities of our products; inability to gain market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; our continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third parties to manufacture, market and distribute many of our products; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in ongoing or future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and
'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
6. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
11. MedImmune Submits Biologics License Application to FDA for Motavizumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the device," Nobel laureate Herbert Kroemer famously observed, ... at the junctures where layers of different materials ... interfaces between layers of metal oxides are becoming ... as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing ...
(Date:1/15/2014)... 2014 The Pittcon Organizing Committee is pleased ... Safety Tech , an e-Journal and producer of ... the second year for the co-location of Food Labs Conference ... provides that the registration fee to attend the two-day Food ...
(Date:1/15/2014)... 2014 Look inside the new Preferred ... the lab, from fluid handling to instruments to supplies. ... when you order. , Preferred Solutions features a ... the L/S® model for precise flow control and dispensing ...
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
Breaking Biology Technology:A deeper look at interfaces 2Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3
... speciality,pharmaceutical company focused on the discovery and development ... problem of microbial,resistance, announces today the appointment of ... (SAB). Novexel,s SAB is chaired by Dr.,David Shlaes ... who is currently,Adjunct Professor at the Department of ...
... /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc.,(NYSE: ... company serving the,pharmaceutical, biotechnology, and medical device industries, ... announced its financial results for,fourth-quarter and full-year 2008. ... ), Highlights, ...
... March 25 David Koos, Chairman and CEO of ... BMSN), told the editors of The Wall Street Transcript, ... is an excellent possibility that the company "would have ... alliances and contracts "with companies engaged either in cryogenic ...
Cached Biology Technology:Novexel Strengthens its Scientific Advisory Board With the Appointment of Dr. Karen Bush 2Novexel Strengthens its Scientific Advisory Board With the Appointment of Dr. Karen Bush 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 20Bio-Matrix Scientific Group CEO Tells Wall Street Transcript That 'Positive Cash Flow' Is Possible in '09; New Stem Cell Banking Facility Is Growth Vehicle Over the Next Two Years, Says CEO in Exclusive News Interview 2
(Date:4/17/2014)... RSV infection , Respiratory syncytial virus (RSV) ... infections, generating life-threating illness in very young and ... limited. RSV enters host cells through the fusion ... bundle. Small interfering peptides that prevent bundle formation ... are highly susceptible to degradation. In this issue ...
(Date:4/17/2014)... NJ. April 16, 2014. Kessler Foundation has been ... million from the Department of Defense Spinal Cord ... principal investigator for the randomized, double-blinded, controlled, multi-site ... bone and muscle strength after spinal cord injury. ... & Engineering Research at Kessler Foundation. Two additional ...
(Date:4/17/2014)... cartridge developed at Sandia National Laboratories and recently licensed ... and cheaper. , Bacillus anthracis , the ... all over the world and can cause serious, and ... bacteria can survive in harsh conditions for decades. In ... through skin contact, inhalation of spores or eating contaminated ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... apparent paradox exists: Despite choosing a career working with ... from mild disgust to extreme arachnophobia. ... Entomologist features the results of a survey involving ... fear of spiders. Although most entomologists had low scores ...
... producing the building blocks of life, amino acids, in research ... The team from Imperial College London, the University of ... icy comets collide into a planet, amino acids can be ... rocky meteorite crashes into a planet with an icy surface. ...
... has a simple message for fellow hypertension researchers: think ... percent of adults have high blood pressure and 50-75 ... powerful endothelin system, which helps the body eliminate salt, ... research and clinical world focus on suppressing a better-known ...
Cached Biology News:Arachnophobic entomologists: When 2 more legs make a big difference 2Scientists discover cosmic factory for making building blocks of life 2Hypertension researcher encourages colleagues to expand their focus 2Hypertension researcher encourages colleagues to expand their focus 3
For cleavage of 6xHis tags from proteins containing a Factor Xa Protease recognition site Efficient 6xHis tag cleavage (greater than 90%), ...
... PBL's bioassays for interferons are cytopathic effect inhibition ... Sample types include; tissue culture supernatents; serum ... these assays, one unit is defined as the ... the cytopathic effect of viral infection by 50%. ...
... The BioPrime Plus Array CGH Genomic Labeling ... enable reproducible labeling of genomic DNA samples ... in both indirect and direct labeling formats, ... Systems provide a flexible solution to your ...
... effect inhibition assays, also known as CPE and ... supernatents; serum from PK studies and delivery formulations. ... as the quantity of interferon required per milliliter ... by 50%. All standards used in ...
Biology Products: